IL9 and cancer: The antitumor effects can be enhanced in combination with an immune checkpoint blockade, indicating a potential translation of the IL-9-expressing oncolytic virus into a clinical trial to enhance the antitumor effects elicited by immune checkpoint blockades for cancer immunotherapy.